Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)

7h globenewswire
Study results confirm safety and tolerability of THR-317 for intra-ocular use, and show improvement in visual acuity for up to 90 days after last injection
THR TBGNF

0
ThromboGenics Plans Name Change to "Oxurion"

2018-06-27 globenewswire
To better reflect Company's activities and ambition to deliver best in class therapies for back of the eye disorders
THR TBGNF

0
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC

2018-06-21 globenewswire
Leuven, Belgium, 21 June 2018 - ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease, announces its participation and support of the seventh annual Prevent Blindness Focus on Eye Health National Summit which takes place on July 18, 2018, at the National Press Club in Washington, DC.
THR TBGNF

0
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)

2018-05-25 globenewswire
Leuven, Belgium, 25 May 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it has successfully enrolled the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898).
THR TBGNF

0
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018

2018-05-23 globenewswire
Leuven, Belgium, 23 May 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group (EASDec) Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland.
THR TBGNF

0
ThromboGenics Business Update - Q1 2018

2018-05-09 globenewswire
Positive Initial Topline Data from Phase 1/ 2a Clinical Study evaluating THR-317, anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)
THR TBGNF

0
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

2018-04-27 globenewswire
Leuven, Belgium, April 27 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it has successfully enrolled the first patient in a Phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis®, Novartis), for the treatment of DME (NCT03499223).
THR TBGNF

0
ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

2018-04-04 globenewswire
30% of anti-VEGF treatment naïve patients had a 3 line or more (> or equal to 15 letters) gain in Best Corrected Visual Acuity (BVCA) after 3 monthly injections with THR-317 (8mg)
THR TBGNF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EBR:THR / THROMBOGENICS on message board site Silicon Investor.

Golf! A thread for the hopelessly addicted! The Exxon Free Environmental Thread
Stock Watcheru0027s Thread / Pix of the Week (POW) Qualcomm Moderated Thread - please read rules before posting
Foreign Policy Discussion Thread The Environmentalist Thread
The New Qualcomm - write what you like thread. NFLX Moderated Thread
Research Frontiers Lonely Hearts Club Thread. Missing Persons SI Thread